

Date and time: **Thursday 4 September 2014, 1000-1600**

Minutes: Confirmed

Guideline Development Group Meeting 2 **Non-alcoholic fatty liver disease (NAFLD)**

Place: **Rosenheim room, RCP, 11 St Andrews Place, London NW1 4LE**

Present: Christopher Byrne, Professor of Endocrinology & Metabolism, University of Southampton
 Chris Day, GDG Chair, Professor of Liver Medicine & Honorary Consultant Hepatologist, Newcastle University
 Irene McGill, Patient/carer representative
 Kevin Moore, Professor of Hepatology, University College London
 Benjamin Mullish, ST in Hepatology & Gastroenterology, Imperial College London (Specialist Trainee Adviser)
 Philip Newsome, Professor of Experimental Hepatology & Honorary Consultant Hepatologist, Birmingham University
 Tanja Pardela, Paediatric Liver Modern Matron, King's College Hospital
 Rachel Pryke, General Practitioner Partner, Winyates Health Centre, Redditch
 Jane Putsey, Patient/carer representative
 Mike Trenell, Professor of Movement & Metabolism & NIHR Senior Research Fellow, Newcastle University (co-opted expert adviser) (present for item 3 only via t/c)
 Indra Van Mourik, Consultant Paediatric Hepatologist & Clinical Lead Liver Unit, Birmingham Children's Hospital NHS Foundation Trust
 Bronwen Williams, Gastroenterology and Hepatology Research Nurse, Hull Royal Infirmary
 Joanna Ashe, Senior Information Scientist, NCGC (present for items 3 and 7)
 Serena Carville, Associate Director, NCGC
 Angela Cooper, Senior Research Fellow, NCGC
 Letteris Floros, Health Economist, NCGC (present for items 1-5)
 Martin Harker, Senior Health Economist, NCGC (present for items 1-5)
 Qudsia Malik, Research Fellow, NCGC
 Amelia Unsworth, Project Manager, NCGC
 Giulia Zuodar, Document Editor/Process Assistant, NCGC (notes)

Apologies: Louise Shires, Guidelines Commissioning Manager, NICE
 David Fitzmaurice, Professor of Primary Care, University of Birmingham

In attendance:

NICE Staff:	Ben Doak, Guidelines Commissioning Manager	
NICE attendee 1		

Observers:

None		
------	--	--

Notes

1. **Welcome, apologies and declarations of interest**

The Chair welcomed the group to the second meeting of this GDG. The following recently-appointed GDG members were welcomed to the group: IMG (patient member) and TP (paediatric liver nurse). MT (expert adviser on exercise physiology) was welcomed to the meeting.

Apologies were received from DF and LS.

The Chair requested updates to the declarations of interest register. No new declarations of interest were received therefore no further action was required. PN confirmed that the study part-funded by Novo Nordisk investigates liraglutide (type 2 diabetes drug) in NAFLD patients. The Chair confirmed that PN should withdraw from the discussions on pharmacological treatment for the extra-hepatic condition type 2 diabetes and only answer direct questions of fact on this topic as requested by the Chair.

2. **GDG1 minutes**

The minutes of the last meeting were agreed as a true and accurate record.

3. **Review questions on referral and diagnosis: health economic considerations**

The GDG discussed the economic considerations for the review questions on referral and diagnosis.

4. **Evidence review: Exercise interventions**

The GDG was given a presentation on the clinical and economic evidence for exercise interventions.

5. **Health economic prioritisation**

The GDG was given a presentation on the health economic prioritisation.

6. **Survey responses**

The GDG survey responses on the draft review questions have been considered.

7. **Review questions & protocols**

The GDG reviewed and agreed a number of review protocols.

8. **Any other business**

None.

Date, time and venue of the next meeting

GDG3: Friday 3 October 2014, 1000-1600, Boardroom, NCGC, 180 Great Portland Street, London W1W 5QZ.